SOURCE: Goldman Small Cap Research, Inc.

September 16, 2013 09:31 ET

Pending High Profile Biotech IPO Should Raise Nuvilex's Valuation

BALTIMORE, MD--(Marketwired - Sep 16, 2013) - In a newly released article, Goldman Small Cap Research, a stock market research firm focused on the small cap and micro cap sectors, notes that there is a buzz in biotech circles regarding the high value of encapsulation technologies and targeted therapy delivery platforms. Firms that have exposure to, or are major participants in these segments are just now beginning to garner significant interest from larger players, thus enabling them to enjoy increasingly favorable valuations. For example, Bind Therapeutics, Inc., a high profile biotech that recently filed to go public via an Initial Public Offering through leading health care investment banks, is one of these companies. Considering the striking similarities between Bind and Nuvilex, Inc. (OTCQB: NVLX), Nuvilex's shares could enjoy a big boost once Bind's IPO registration becomes effective.

Bind is developing a therapy using what it terms Accurins. Accurins are polymeric nanoparticles that incorporate a therapeutic payload and are designed to have prolonged circulation within the bloodstream, enable targeting of the diseased tissue or cells, and provide for the controlled and timely release of the therapeutic payload at the site of disease to enhance efficacy while minimizing adverse effects on healthy tissues.

Bind's nanomedicine platform for developing targeted therapies to treat forms of cancer has caught the eye of big pharma. The Company, which has two Phase II cancer clinical trials in progress, has already received $13M in milestone payments. To date, Bind has announced collaborations with Amgen, Pfizer and AstraZeneca to develop Accurins based on therapeutic payloads from their product pipelines, with the potential to achieve a total of over $1 billion in upfront and future milestone payments, including over $450 million in pre-commercial milestones.

If the description of the Bind Therapeutics approach sounds familiar to Nuvilex investors, it should. Both companies are engaged in developing a platform approach to targeted therapies using a prodrug to treat the targeted cancerous tissues and cells directly at the site with fewer side effects than traditional treatments. Both firms' technology could potentially be used in conjunction with currently approved drugs for the treatment of many different forms of cancer by optimizing the anticancer activity of such drugs.

As evidenced by the development deals with big pharma, Bind Therapeutics may be ahead of Nuvilex for the time-being but we believe that Nuvilex's stock trading pattern will closely mirror that of Bind's and that the Company will greatly benefit from Bind's likely high valuation as a consequence of the latter's IPO.

To view all of our sponsored Nuvilex reports, updates, articles, disclosures and disclaimers, or to download the article in its entirety, please visit

About Goldman Small Cap Research: Led by former Piper Jaffray analyst and mutual fund manager Rob Goldman, Goldman Small Cap Research produces sponsored and non-sponsored small cap and micro cap stock research reports, articles, daily stock market blogs, and popular investment newsletters. Goldman Small Cap Research is not in any way affiliated with Goldman Sachs & Co.

A Goldman Small Cap Research report, update, newsletter, or article is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed. Please read all associated full disclosures, disclaimers, and analyst background on our website before investing. Neither Goldman Small Cap Research nor its parent is a registered investment adviser or broker-dealer with FINRA or any other agency. To download our research, view our disclosures, or for more information, visit

About Nuvilex, Inc. (OTCQB: NVLX): Nuvilex, Inc. is an international biotechnology firm focused on developing and preparing to commercialize treatments for cancer, diabetes and other diseases based on the live, therapeutically valuable, encapsulated cells platform. The Company is leveraging its cancer biology and clinical oncology research experience and expertise, particularly for use in oncology treatments, in addition to initiating oncology applications of medical marijuana. For more information visit:


Contact Information